Guanidinoacetic Acid Supplementation: A Mechanistic Model of Utilization and Clearance

Guanidinoacetic acid, the immediate precursor of creatine, is gaining renewed attention as a nutritional and therapeutic agent capable of enhancing tissue bioenergetics. Yet, a comprehensive mechanistic framework describing how exogenous guanidinoacetic acid is processed in the human body is lacking. This concept paper proposes an integrated metabolic model of guanidinoacetic acid utilization, synthesizing available kinetic evidence on its enzymatic conversion via guanidinoacetate N-methyltransferase (GAMT), cellular trafficking through the creatine transporter (SLC6A8), and ancillary routes including reverse amidinotransferase activity, oxidative degradation, and renal handling. Our modeling reveals that GAMT achieves near-saturation at relatively low guanidinoacetic acid intakes, whereas SLC6A8 transport capacity remains underutilized even at higher systemic guanidinoacetic acid levels due to competitive interactions with creatine. Secondary pathways contribute proportionally less to overall guanidinoacetic acid fate but may assume greater importance in metabolic stress, aging, or creatine-deficiency states. By estimating theoretical distributions of guanidinoacetic acid flux across these pathways for commonly used oral doses (1-4 g/day), this manuscript provides a mechanistic foundation for optimizing guanidinoacetic acid supplementation strategies. The model highlights clinically relevant opportunities-such as enhancing creatine repletion, supporting mitochondrial function, and addressing creatine-deficiency syndromes-while identifying key parameters that require in vivo validation. Collectively, this work aims to guide both basic researchers and clinicians toward a more informed and strategic use of guanidinoacetic acid in human nutrition and health.